Wedbush analyst Laura Chico initiated coverage of BioCryst (BCRX) with an Outperform rating and $15 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Promising Pipeline and Market Position Drive Buy Rating
- BioCryst selloff yesterday brings buying opportunity, says JPMorgan
- BioCryst’s Strong Growth Potential and Pipeline Advancements Justify Buy Rating
- BioCryst Pharmaceuticals Reports Strong 2024 Revenue Growth
- BioCryst’s Growth Prospects: Buy Rating Backed by Revenue Guidance and Pipeline Developments